More from these Authors

• Article | Cambridge Journal of Regions, Economy and Society | March 2019

  The New Silk Road: Implications for Higher Education in China and the West?

  William C. Kirby and Marijk C. van der Wende

  Recent geopolitical events, such as Brexit and the retreat from multilateral trade and cooperation by the USA, have created waves of uncertainty, especially in the field of higher education, regarding international cooperation. Meanwhile, China is publicly seeking to take the lead in globalisation, developing its higher education and research systems at speed and actively seeking to cooperate with academic partners along the New Silk Roads in order to attract talent (back). But under which conditions, whose definitions, and based on what values? And what, if any, difference will the “New Silk Road” make in the global educational landscape?

  Keywords: New Silk Road; Globalization; Higher Education; Global Range; International Relations; Cooperation;

  Citation:

  Kirby, William C., and Marijk C. van der Wende. "The New Silk Road: Implications for Higher Education in China and the West?" Cambridge Journal of Regions, Economy and Society 12, no. 1 (March 2019): 127–144.  View Details

  CiteView DetailsFind at Harvard Read Now Purchase

  Related

• Other Presentation | 28 Feb 2019

  Perspectives on Chinese Investment in the United States: Testimony for the USCC

  William C. Kirby

  Citation:

  Kirby, William C. "Perspectives on Chinese Investment in the United States: Testimony for the USCC." Hearing on 'Risks, Rewards, and Results: U.S. Companies in China and Chinese Companies in the United States', U.S.-China Economic and Security Review Commission (USCC), Washington, DC, February 28, 2019.  View Details

  CiteView Details Read Now

  Related

• Case | HBS Case Collection | March 2018 (Revised January 2019)

  Gilead Mexico

  Michael Chu and V. Kasturi Rangan

  With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of Gilead Mexico, the challenge was complicated by operating in a middle-income country, where Gilead’s terms for more vulnerable nations did not apply. For all practical purposes, Musalem had only one customer for his company’s Hep C medicine: Mexico’s public health system and the National Pricing Commission that set prices annually for the entire sector. With no lack of priorities competing for the finite resources of the public health sector, Musalem’s charge was to devise the strategy that in the long run would maximize access to the cure in Mexico while protecting the financial strength of Gilead Sciences, Inc.

  Keywords: Health Care and Treatment; Price; Strategy; Management; Pharmaceutical Industry; Mexico;

  Citation:

  Chu, Michael, and V. Kasturi Rangan. "Gilead Mexico." Harvard Business School Case 318-111, March 2018. (Revised January 2019.)  View Details

  CiteView DetailsEducatorsPurchase

  Related